http://www.ijmrps.com/index.php/ijmrps en-US editor@ijmrps.com (Editor IJMRPS) ijmrpsjournal@gmail.com (Technical Support) Mon, 08 Apr 2024 05:48:30 +0000 OJS 3.3.0.8 http://blogs.law.harvard.edu/tech/rss 60 http://www.ijmrps.com/index.php/ijmrps/article/view/61 <p>Introduction: Glioblastoma multiforme, the most aggressive primary tumor of the central nervous system (CNS) with a poor prognosis. Despite several clinical studies conducted over many years, our capacity to significantly influence the survival outcomes for these patients remains fairly limited.</p> <p>Aim of the study: To evaluate patient demographics and treatments commenced in patients with glioblastoma to study their survival rate and to investigate their prognostic factors of survival.</p> <p>Methods: A retrospective analysis of newly diagnosed radiologically and/or histologically confirmed glioblastoma patients referred to our clinic at the Military Oncology Center in the period between January 2020 and December 2022. Patient demographics, treatment details, and survival data were collected. Kaplan-Meier survival curves were utilized to characterize univariate associations between age and survival. We constructed a Cox proportional hazard model that incorporated multivariate survival predictors.</p> <p>Results: A total of 123 patients with a mean age at diagnosis of 55 ± 16.2 were included in this study. Overall survival was 9.8 months. Univariate analyses showed that younger age was associated with a longer survival, with a median survival of 13.2 months in patients aged less than 50 years versus 7.6 months in patients aged 50 or more. In the multivariate analysis, better survival was associated with debulking surgery vs. biopsy alone (15 vs. 8 months) (HR 0.54, 95% CI 0.41–0.70), subsequent treatment after diagnosis, standard chemoradiotherapy (16.5 months) vs. nonstandard regimens (10.3 months) vs. radiotherapy alone (5.4 months), and palliative radiotherapy (2 months).</p> <p>Conclusion: The median survival rate for the patients included in the study was less than one year. Younger age, debulking surgery, and treatment with chemoradiotherapy are independently associated with longer survival.</p> Hana Ahmed Al-Mahasneh, MD, Anfal Nasr Daheerat, MD, Tamer Hani Haddad, MD, Manar Hasan Hayajneh, MD, Mohammad Amin Omar, Medical Physicist, Abdaljleel Mohammad Al-Shrrayah, MD, Jamilah Sarayirah,MD, Hayat Kh. Khasawneh,MD Copyright (c) 2024 http://www.ijmrps.com/index.php/ijmrps/article/view/61 Mon, 08 Apr 2024 00:00:00 +0000